Startup profile for Gate Bioscience: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.
Venture Capital Tracker logo
Venture Capital Tracker

Startup profile · funding coverage

Gate Bioscience funding, valuation and investors

Biotech developing oral Molecular Gate medicines that eliminate disease-causing proteins.

Keep track of Gate Bioscience

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series B

$65M · November 2025

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$125M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series b · Brisbane, California

Investors in latest funding

Lead: Forbion

Other: Andreessen Horowitz , ARCH Venture Partners

Sources: latest funding Last verified: 2026-07-25

Overview

Gate Bioscience develops oral small-molecule drugs using its Molecular Gate platform — blocking secretion of disease-causing proteins rather than inhibiting them inside cells. The company operates under the Gate Bio brand.

Why Gate Bioscience is interesting

Gate Bioscience's differentiated protein-secretion blockade attracted ARCH and a16z across a $60M Series A and $65M Series B.

Product & use cases

Gate Bioscience (Gate Bio brand) develops oral molecular gate medicines blocking secretion of disease-causing proteins.

  • Inflammatory disease programs toward clinic
  • Neurological targets including prion disease
  • Lilly partnership for difficult protein targets

Key facts

  • Series A (2023): $60M co-led by Versant Ventures and a16z Bio + Health (/fund/andreessen-horowitz) with ARCH Venture Partners (/fund/arch-venture-partners) (BioCentury)
  • Series B (2025): $65M with ARCH among existing investors (Gate Bio press)

Funding history (newest first)

Series B

2025-11 $65M

Source: https://www.gatebio.com/gate-bioscience-announces-65-million-oversubscribed-series-b-financing-to-advance-oral-molecular-gate-medicines-into-the-clinic

Series A

2023 $60M

Source: https://endpoints.news/gate-bioscience-captures-another-65m-with-new-take-on-protein-degradation/

Investors in our directory

Funds linked from Gate Bioscience's profile — open a fund page for stage focus and related deal articles.

Andreessen Horowitz ARCH Venture Partners

Competitive landscape

Edge: Secretion-pathway mechanism with oral delivery; platform repeatability across secreted targets.

Gate's molecular gates target secretory biology — less crowded than general degraders. Clinical POC in 2028 timeframe per CEO statements.

  • Arvinas (PROTAC) adjacent

    Intracellular degradation; Gate eliminates pre-secretion.

  • Monte Rosa Therapeutics adjacent

    Molecular glue degraders.

  • Biologics incumbent

    Injectable; Gate offers oral small-molecule alternative.

Notable stories

  • Operates under Gate Bio brand — see also /startup/gate-bio.
  • Lilly partnership up to $856M (Endpoints News, July 2025).

Industries

Biotech & Life Sciences

FAQs about Gate Bioscience

Practical answers founders, operators, and investors typically search for.

Gate Bioscience develops oral molecular gate medicines blocking secretion of disease-causing proteins.
a16z Bio + Health (/fund/andreessen-horowitz) co-led Series A. ARCH (/fund/arch-venture-partners) re-upped in Series B.
Same company — Gate Bio is the brand name.
Oral small molecules preventing secretion of disease-causing proteins at the source.
Series B — $65M in November 2025.
Inflammatory and neurological diseases including prion disease.
Brisbane, California.
Many disease proteins are secreted — molecular gates offer oral medicines for that class.
No — remains private.
Website All startups Funding news

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.